FINDEX Inc.

Tokyo Stock Exchange 3649.T

FINDEX Inc. EBITDA Margin for the year ending December 31, 2023: 34.33%

FINDEX Inc. EBITDA Margin is 34.33% for the year ending December 31, 2023, a 18.47% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

FINDEX Inc. EBITDA Margin for the year ending December 31, 2022 was 28.98%, a 14.92% change year over year.
FINDEX Inc. EBITDA Margin for the year ending December 31, 2021 was 25.21%, a -1.51% change year over year.
FINDEX Inc. EBITDA Margin for the year ending December 31, 2020 was 25.60%, a -6.22% change year over year.
FINDEX Inc. EBITDA Margin for the year ending December 31, 2019 was 27.30%, a -1.63% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tokyo Stock Exchange: 3649.T

FINDEX Inc.

CEO	Mr. Teruo Aibara
IPO Date	March 23, 2011
Location	Japan
Headquarters	Asahiseimei-Otemachi Building
Employees	290
Sector	Health Care
Industries Medical Instruments Pharmaceuticals

Description

FINDEX Inc. engages in the research and development, manufacture, and sale of medical systems in Japan. The company's products include Claio, a medical imaging database management system for small, medium, and large size hospitals; and C-Note, a progress note system. It also offers DocuMaker, a document and data management system, which provides various input tools to enhance productivity in document creation; and GAP/GAP-screener, a gaze analyzing perimeter. In addition, the company develops applications for smart phone. It serves medical institutions, hospitals, and clinics. The company was formerly known as PSC Inc. and changed its name to FINDEX Inc. in November 2014. FINDEX Inc. was founded in 1985 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years